Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Active not recruiting 20Recruiting 11Completed 4Terminated 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Head & Neck 1Endocrine 1

Conditions

Melanoma 2Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1

Interventions

pembrolizumab 66Cyclophosphamide 44Cisplatin 43Nivolumab 36Paclitaxel 32Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Doxorubicin 19Bevacizumab 19Magnetic Resonance Spectroscopy 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Radiosurgery 15Letrozole 15Ipilimumab 15Fluorouracil 15Blood Specimen Collection 15palbociclib 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14Surveys and Questionnaires 13Specimen Handling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × trametinib × 90 days × Clear all
NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed
603 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

NCT01682083 2026-04-21

COMBI-AD

Novartis

Phase 3 Completed
870 enrolled 15 charts 1 FDA
Dermatologic

Melanoma, Neoplasms

NCT03244956 2026-03-23

MERAIODE

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
40 enrolled
EndocrineHead & Neck

Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡